TNFSF10 and neoplasm: The combination of Rg3 (oral dose of 20 mg/kg, daily for 21 days) and TRAIL (intraperitoneal 3 times per week at dose of 3 mg/kg, for 21 days) reduced tumor volume in in vivo mouse xenograft model compared with control group along with enhancing TUNEL-positive cells and cleaved caspase-3–positive cells in tumor sections [65].